NEW YORK, Jan. 8 /PRNewswire-FirstCall/ -- AngioGenex, Inc. , a New York-based biotechnology company, and the category leader in Id targeted drug discovery and development, announced today that a publication in the scientific journal Nature Biotechnology by Dr. Robert Benezra, a Member at Memorial Sloan Kettering Cancer Center and the Head of AngioGenex's Scientific Advisory Board, provided proof that Id proteins are anti-angiogenic targets for cancer prevention. Using a novel biologic molecule targeting the Id-1 protein in mice, Dr. Benezra achieved tumor suppression by blocking blood vessel formation, or angiogenesis. A free abstract and the entire manuscript are available online at http://www.nature.com/nbt/journal/vaop/ncurrent. Additional data in the report demonstrates that Id-Inhibition has a profound impact on tumor metastasis further illustrated the essential role Id plays in the establishment and growth of cancers. According to Benezra: "The effectiveness and low toxicity of these Id1-targeting agents, called PCAOs, appear better in preclinical models than the current anti-VEGF drugs on the market or in clinical development." He concluded that: "The data validates our predictions based on the genetics we and others have performed over the past ten years and moves us much closer toward clinical application."
William Garland, the Head of Research and Development at AngioGenex echoed Benezra's enthusiasm: "AngioGenex is committed to developing drugs that prevent tumor formation and metastasis by inhibiting the formation and/or biological action of Id proteins. Benezra's latest work is a significant advance towards meeting this corporate goal. The work strongly validates the essential nature of the Id genes and proteins as useful cancer targets while also demonstrating that the targets are drugable by conventional means. These important new findings confirm that an anti-Id approach offers a practical method for diminishing angiogenesis and thereby reducing the growth and metastasis of tumors."
AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer drugs that prevent the formation of new blood vessels into tumors (angiogenesis) by inhibiting the action of either the Id genes or proteins. The company's proprietary technology is based primarily on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. He established that the Id genes are required for the formation of the new blood vessels that allow tumors to grow and to metastasize. In animals, the absence of the Id genes resulted in a highly significant inhibition of growth of a number of lethal tumors and a reduction in size of mature, established tumors. Dr. Benezra's research has been recognized by leaders in the angiogenesis community for its important therapeutic implications. The company's research also shows promise for the treatment of ocular diseases such as diabetic retinopathy and age related macular degeneration.
Others have demonstrated that blocking blood vessel formation is useful to treat some tumors in humans for which there are only limited and unsatisfactory therapies. As a result, anti-angiogenesis therapy has been hailed in medical circles as the first new and promising approach for cancer treatment in many years. "The Id mechanism has been demonstrated in the highest levels of the academic community to play an indispensable role in the creation of the new blood vessel networks that cancers need to grow and spread," according to Vice-President Michael Strage. "AngioGenex is in a unique proprietary position to exploit these findings and build a business around the development of pharmaceutical products that can control tumorigenesis and metastasis through Id-inhibition."
This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the ability of AngioGenex to raise substantial additional financing, to complete clinical development of AngioGenex products, and the ability of the company to successfully develop and market AngioGenex products and technologies. These statements represent the judgment of management as of this date and are subject to risks and uncertainties that could materially affect the company. AngioGenex undertakes no obligation to publicly release the results of any revisions to such forward-looking statements that may be made to reflect recent events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: Michael Strage V.P., Corporate Communications and Investor
Relations of AngioGenex, Inc., +1-212-874-6608, or Cell, +1-646-642-0701,
or Fax, +1-212-874-5027
Web site: http://www.angiogenex.com/